Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Immunocore

8 clinical trials

Clinical trial
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Status: Active (not recruiting), Estimated PCD: 2020-10-13
Clinical trial
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Participants With Chronic HBV Infection Who Are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed
Status: Recruiting, Estimated PCD: 2024-09-10
Clinical trial
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Status: Terminated, Estimated PCD: 2023-09-25
Clinical trial
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Status: Completed, Estimated PCD: 2023-06-19
Clinical trial
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Status: Completed, Estimated PCD: 2020-03-20